ArticleLiver international : official journal of the International Association for the Study of the Liver2021
The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Health care costs associated with disease progression of untreated chronic hepatitis C in the United States.Journal of managed care & specialty pharmacy · 2026Observational
- Assessing the Long-Term Impact of the COVID-19 Pandemic on Hospital Outcomes in Patients with Decompensated Liver Cirrhosis.Medicina (Kaunas, Lithuania) · 2026Article
- Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study.Pathogens (Basel, Switzerland) · 2025Article
- Article
- The Impact of New Direct-Acting Antiviral Therapy on the Prevalence and Undiagnosed Proportion of Chronic Hepatitis C Infection in Alberta: A Model-Based Analysis.Canadian liver journal · 2025Article
- Disparities in Peripheral Artery Disease-related Mortality in Chronic Inflammatory Disease in the United States from 1999 to 2020.Current cardiology reviews · 2025Article
- The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status.Journal of clinical medicine · 2024Article
- Screening strategy to advance HCV elimination in Italy: a cost-consequence analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Aspects that facilitate access to care for viral hepatitis: An evaluative research.Sao Paulo medical journal = Revista paulista de medicina · 2024Article
- Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey.JHEP reports : innovation in hepatology · 2022Article
- Taxonomic Characterization, Antiviral Activity and Induction of Three New Kenalactams in Nocardiopsis sp. CG3.Current microbiology · 2022Article
- Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain.PloS one · 2022Article
- Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries.Liver international : official journal of the International Association for the Study of the Liver · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
aimsWe assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain.
methodsAn HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus disease (COVID-19) was also developed.
resultsThe estimated number of avoided hepatocellular carcinoma, decompensated cirrhosis and liver transplantations over a 20-year time horizon was: 1,057 in England; 1,221 in Italy; 1,211 in Romania; and 1,103 in Spain for patients treated during 2015-2016 and 640 in England; 626 in Italy; 739 in Romania; and 643 in Spain for patients treated during 2017-2019. The cost-savings ranged from € 45 to € 275 million. The investment needed to expand access to DAAs in 2015-2019 is estimated to be recovered in 6.5 years in England; 5.4 years in Italy; 6.7 years in Romania; and 4.5 years in Spain. A delay in treatment because of COVID-19 will increase liver mortality in all countries.
conclusionDirect-acting antivirals have significant clinical benefits and can bring substantial cost-savings over the next 20 years, reaching a Break-even point in a short period of time. When pursuing an exit strategy from strict lockdown measures for COVID-19, providing DAAs should remain high on the list of priorities in order to maintain HCV elimination efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.